News and Events
Sharing Stories of
Patients, Employees
and Communities
Featured News
October 26, 2021
Alkermes Initiates ARTISTRY-7 Phase 3 Trial of Nemvaleukin Alfa in Patients With Platinum-Resistant Ovarian Cancer
October 25, 2021
Alkermes Receives FDA Fast Track Designation for Nemvaleukin Alfa in Combination With Pembrolizumab for the Treatment of Platinum-Resistant Ovarian ...
COVID-19 Response
In response to the urgent and unexpected needs created by the COVID-19 pandemic, Alkermes acted quickly to prioritize the safety of our employees and our communities, and adapted our business practices to support uninterrupted supply of, and patient and provider access to, our marketed and investigational medicines.
Lessons from Leadership
Senior Director and Research Oncology Program Lead Heather Losey, Ph.D. shares five leadership lessons she’s learned throughout her career as part of an Authority Magazine series highlighting inspirational women in STEM.
Building for the Future
In a recent interview with Informa Connect's Xconomy, our Chief Operating Officer, Blair Jackson, discusses our ambitions and our evolving strategy in neuroscience and oncology.
Media Resources
Company Description
Alkermes is focused on developing innovative medicines that seek to address unmet needs of people living with serious mental illness, addiction and cancer. As a fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we apply our scientific expertise and proprietary technologies to develop products designed to make a meaningful difference in the way people manage their diseases. Beyond our scientific pursuits, we also work to help support and enhance the systems through which these complex diseases are treated. We are committed to patient engagement, disease education and supporting policies that enable access to approved treatment options.
Follow us on our social channels
